Pacira BioSciences Welcomes New Chief Financial Officer
Pacira BioSciences, Inc. (NASDAQ: PCRX), a pioneer in innovative, non-opioid pain therapies, has recently appointed Shawn Cross as its Chief Financial Officer. This pivotal role will see Mr. Cross overseeing all financial operations as the company focuses on growth and value creation.
Leadership Vision and Commitment to Innovation
The CEO of Pacira, Frank D. Lee, expressed his excitement about Mr. Cross joining the leadership team. "We are delighted to welcome Shawn and look forward to his guidance in investing in long-term growth," he stated. Mr. Cross's experience in finance and his alignment with the company's mission to transform patient lives will be invaluable.
A Background in Biotechnology and Investment
With over 25 years of experience in the biotechnology sector, Mr. Cross has a distinguished career that includes roles as a board member and investment banker. Before joining Pacira, he held significant positions at Applied Molecular Transport, Inc. (AMT), where he was instrumental in the company's growth and eventual merger with Cyclo Therapeutics, Inc. (NASDAQ: CYTH).
Strategic Financial Growth and Inducement Awards
To support Mr. Cross’s role at Pacira, the Compensation Committee of the Board approved inducement awards contingent upon his appointment. These awards include a non-qualified stock option for purchasing shares of the company's common stock, along with a restricted stock unit award, both designed to enhance Mr. Cross's commitment and contributions to the company.
Pacira's Commitment to Non-Opioid Solutions
Pacira is dedicated to transforming the treatment landscape for pain management. Their suite of commercial-stage products includes EXPAREL®, ZILRETTA®, and ioveraº®, which represent innovative, non-opioid alternatives for managing pain. The company is also advancing PCRX-201, a novel gene therapy aimed at treating widespread conditions such as osteoarthritis.
Educational and Professional Foundation
Mr. Cross's educational background includes a B.S. in Kinesiology from the University of California, Los Angeles, and an M.B.A. from Columbia Business School. This robust academic foundation complements his extensive hands-on experience in the biopharmaceutical landscape.
Frequently Asked Questions
What is the new role of Shawn Cross at Pacira BioSciences?
Shawn Cross has been appointed as the Chief Financial Officer, overseeing all financial operations.
What experience does Shawn Cross bring to his new position?
Mr. Cross has over 25 years of experience as a biotechnology executive and investment banker, enhancing his capability to lead financial strategies at Pacira.
What are Pacira's primary products?
Pacira's significant products include EXPAREL®, ZILRETTA®, and ioveraº®, which provide innovative non-opioid pain management solutions.
How does Pacira support its new CFO?
To incentivize Mr. Cross's contributions, the Board approved inducement awards, including stock options and restricted stock units.
What is the mission of Pacira BioSciences?
Pacira BioSciences aims to transform patient care through innovative, non-opioid pain therapies that improve health outcomes.
